Contáctenos
Acerca de la compañía
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
US
Desconocido
Empresa no verificada
Transparencia empresarial
- No verificó la información de la empresa
- Pide reseñas a sus clientes
- No respondió a las críticas negativas.